These trials showed clinically major pharmacokinetic interactions [7] characterised by a minimize while in the clearance in the anticancer drug and for this reason enhanced exposure. The interpretation of subsequent phase II and III medical trials was intricate because it was not possible to administer the exact same dose of chemotherapy during the
To guage the result of zosuquidar within the pharmacokinetics of daunorubicin, blood samples were being received from the primary 100 patients enrolled from nine ECOG web-sites. Samples were being drawn straight away right before and at 6 specified time intervals after the 3rd dose of daunorubicin in the course of the to start with class of inducti
Manual article review is required for this article
Manual article review is required for this article